Source comparison
Ipamorelin Half Life vs Other Growth Hormone Secretagogues
The pharmacokinetic profile of ipamorelin half life becomes clearest when compared directly to other peptides and small molecules in the growth hormone secretagogue class. Understanding these differences is essential for selecting the appropriate compound base
This comparison does not assign a generated winner or score.
- The pharmacokinetic profile of ipamorelin half life becomes clearest when compared directly to other peptides and small molecules in the growth hormone secretagogue class. Understanding these differences is essential for selecting the appropriate compound based on research objectives. Whether the goal is acute GH pulse generation, sustained elevation, or receptor pharmacology studies.
- Ipamorelin
- ~2 hours
- 30–45 min
- 3–4 hours
- Highly selective GHS-R1a, no cortisol/prolactin
- 2–3× daily for sustained effect
- GHRP-6
- ~30 minutes
- 20–30 min
- 2–3 hours
- GHS-R1a agonist, significant cortisol/prolactin elevation
- 3–4× daily
- GHRP-2
- GHS-R1a agonist, moderate cortisol/prolactin increase
- Hexarelin
- ~70 minutes
- 30–40 min
- GHS-R1a agonist, desensitization occurs rapidly
- Not suitable for chronic use
- CJC-1295 (no DAC)
- GHRH analog, synergizes with GHRPs
- 2–3× daily, often stacked
- CJC-1295 with DAC
- 6–8 days
- 24–48 hours
- Weeks
- GHRH analog, sustained release
- Once weekly
- MK-677 (Ibutamoren)
- 24 hours
- 2–4 hours
- 24+ hours
- GHS-R1a agonist, oral bioavailability
- Once daily
- The ipamorelin half life of 2 hours positions it as the longest-acting injectable GHRP while maintaining the selectivity profile that prevents off-target hormone elevation. GHRP-6 and GHRP-2 have half lives under 60 minutes, requiring more frequent dosing and often producing cortisol and prolactin increases that confound metabolic research. Hexarelin, despite similar potency, causes rapid receptor desensitization after 2–4 weeks of daily use. A phenomenon ipamorelin does not trigger even with chronic administration.
- CJC-1295 without DAC (also called Modified GRF 1-29) has a half life similar to GHRP-6 but acts on GHRH receptors rather than ghrelin receptors. Making it synergistic when stacked with ipamorelin. The CJC1295 Ipamorelin 5MG 5MG combination amplifies GH pulse amplitude without extending the ipamorelin half life, as each peptide works through a distinct receptor mechanism. CJC-1295 with DAC extends half life to nearly a week through albumin binding, producing sustained GH elevation rather than discrete pulses. Fundamentally different from ipamorelin's pulsatile profile and often associated with side effects like water retention and carpal tunnel symptoms not seen with shorter-acting peptides.
- MK-677 is an orally bioavailable small molecule ghrelin mimetic with a 24-hour half life, making once-daily dosing convenient. However, chronic daily MK-677 produces continuous GH elevation rather than pulsatile secretion, which more closely resembles exogenous GH administration than endogenous physiology. Research comparing pulsatile (ipamorelin) vs continuous (MK-677) GH secretagogue protocols has found differential effects on insulin sensitivity, with pulsatile protocols showing less insulin resistance over time. The ipamorelin half life allows a return to baseline between doses, preserving the natural pulsatile rhythm that appears important for metabolic outcomes.